Ontology highlight
ABSTRACT: Objectives
To assess the cost-effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer from the US healthcare sector perspective with a lifetime horizon.Methods
We built a partitioned survival model based on a network meta-analysis of 7 clinical trials with 7287 patients aged 36 to 94 years between 2004 and 2018 to predict patient health trajectories by treatment. We tested parameter uncertainties with probabilistic sensitivity analyses. We estimated drug acquisition costs using the Federal Supply Schedule and adopted generic drug prices when available. We measured cost-effectiveness by an incremental cost-effectiveness ratio (ICER).Results
The mean costs were approximately $392 000 with androgen deprivation therapy (ADT) alone and ap
SUBMITTER: Wang L
PROVIDER: S-EPMC9844549 | biostudies-literature | 2022 May
REPOSITORIES: biostudies-literature